Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRLD
DateTimeSourceHeadlineSymbolCompany
09/05/202412:01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202412:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
07/05/202412:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202412:01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202421:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202421:35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202421:45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202422:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202421:05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202421:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202421:05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202421:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
08/01/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202314:34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202314:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202317:30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
06/10/202314:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/08/202313:30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
03/08/202313:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD